UNSPSC 51363402: Capuride

This classification denotes a sedative and hypnotic with the molecular formula C9H18N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3FO9QT93IS, chemically known as urea, (2-ethyl-3-methylvaleryl)- (8ci) but generally known as capuride, which bears US NIH Compound Identifier 231285. European Medicines Agency schedules Capuride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06082MIG. The term CAPURIDE is an International Non-Proprietary Name.

UNSPSC 51363402 Capuride, a Commodity code, does not map cleanly to the state and local opportunities recently posted under this classification. The three recent solicitations show minimal or no connection to capuride specifically; instead, they address broader pharmaceutical and health-related procurement: naloxone and drug deactivation systems, therapeutic pharmacy initiatives and direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers. The mismatch suggests either a coding inconsistency in the source data or that capuride itself does not drive meaningful recent state and local demand. Issuing bodies entering these pharmaceutical-adjacent categories include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities across multiple jurisdictions including Oregon).

Activity appears concentrated in Florida, Texas, and the upper Midwest (Minnesota and participating states). Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. The Seminole County bid carried a two-year initial term with optional one-year renewal and fixed-fee pricing; MMCAP's contract runs two years for new vendors with discretionary extensions. Neither opportunity identified explicit set-asides or disadvantaged-enterprise restrictions. If capuride procurement exists in state and local markets, it does not surface in recent posted opportunities; this code warrants verification against actual buying patterns before committing business development resources.